Association of aging acceleration with serum neurofilament light chain levels: Implications for the roles of modifiable aging factors

被引:0
|
作者
Tang, Liwei [1 ]
Liu, Min [2 ]
Tao, Yifan [3 ]
Ranson, Janice M. [4 ]
Napolioni, Valerio [5 ]
Wang, Haidong [1 ]
Huang, Jie [1 ]
机构
[1] Southern Univ Sci & Technol, Dept Sch Publ Hlth & Emergency Med, 1088 Xueyuan Ave, Shenzhen 518055, Peoples R China
[2] Chinese Acad Sci, Brain Cognit & Brain Dis Inst, Shenzhen Inst Adv Technol, 1068 Xueyuan Ave, Shenzhen 518055, Guangdong, Peoples R China
[3] Johns Hopkins Univ, Sch Engn, 3400 N Charles St, Baltimore, MD 21218 USA
[4] Univ Exeter, Med Sch, Heavitree Rd, Exeter EX12LU, England
[5] Univ Camerino, Sch Biosci & Vet Med, Piazza Cavour 19-F, I-62032 Camerino, Italy
关键词
Aging; Age acceleration; Neurodegenerative diseases; Neuroaxonal damage; Neurofilament light chain; OXIDATIVE STRESS; NEURODEGENERATIVE DISEASE; INSULIN; DYSFUNCTION; PROTEIN; AGE;
D O I
10.1016/j.jad.2024.12.023
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Neurofilament light chain (NfL) is a specific biomarker of neuroaxonal damage and related neurodegenerative diseases. Aging acceleration, which reflects the impact of modifiable factors on the aging process, is increasingly recognized for its relevance. While normal aging is known to contribute substantially to neuroaxonal damage and many neurodegenerative diseases, the effects of aging acceleration warrant further investigation. This study aimed to investigate the association and causality between aging acceleration and serum NfL levels. Methods: We conducted a cross-sectional study involving 1695 adult participants from NHANES 2013-2014 to evaluate the association, dose-response relationship, and interaction network between aging acceleration and serum NfL levels. And we used Mendelian randomization (MR) to assess the causal effects between serum NfL levels and aging acceleration. Results: Significant positive associations were observed between aging acceleration and serum NfL levels. In linear regression, the regression coefficients were 0.016 (95 % CI: 0.011-0.021) for biological age acceleration and 0.020 (95 % CI: 0.012-0.028) for phenotypic age acceleration. In logistic regression, the odds ratios were 1.052 (95 % CI: 1.029-1.076) and 1.093 (95 % CI: 1.064-1.123), respectively. Restricted cubic spline regression identified significant positive dose-response relationships, and bidirectional MR analyses demonstrated forward causal effects. Conclusion: Our study indicates that aging acceleration is significantly associated with serum NfL levels, with higher levels of aging acceleration linked to an increased risk of neuroaxonal damage. These findings provide robust evidence that aging acceleration affects the risk of neuroaxonal damage and highlight the importance of modifiable aging factors.
引用
收藏
页码:481 / 490
页数:10
相关论文
共 50 条
  • [31] Cerebrospinal Fluid and Serum Neurofilament Light Chain Levels in ALS Patients
    Simone, Isabella L.
    Ruggieri, Maddalena
    Tortelli, Rosanna
    D'Errico, Eustachio
    Leo, Antonio
    Mastrapasqua, Mariangela
    Leante, Rosaria
    Capozzo, Rosa
    Livrea, Paolo
    Logroscino, Giancarlo
    NEUROLOGY, 2010, 74 (09) : A179 - A180
  • [32] Serum neurofilament light chain in MS: association with clinical and MRI measures
    Oldoni, E.
    Smets, I.
    Gille, B.
    Mallants, K.
    Poesen, K.
    Dubois, B.
    Goris, A.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 885 - 885
  • [33] Association of serum neurofilament light chain and bone mineral density in adults
    Meihong Lan
    Mingming Gao
    BMC Musculoskeletal Disorders, 26 (1)
  • [34] Association of neurofilament light chain with renal function: mechanisms and clinical implications
    Tang, Rongxiang
    Panizzon, Matthew S.
    Elman, Jeremy A.
    Gillespie, Nathan A.
    Hauger, Richard L.
    Rissman, Robert A.
    Lyons, Michael J.
    Neale, Michael C.
    Reynolds, Chandra A.
    Franz, Carol E.
    Kremen, William S.
    ALZHEIMERS RESEARCH & THERAPY, 2022, 14 (01)
  • [35] Association of neurofilament light chain with renal function: mechanisms and clinical implications
    Rongxiang Tang
    Matthew S. Panizzon
    Jeremy A. Elman
    Nathan A. Gillespie
    Richard L. Hauger
    Robert A. Rissman
    Michael J. Lyons
    Michael C. Neale
    Chandra A. Reynolds
    Carol E. Franz
    William S. Kremen
    Alzheimer's Research & Therapy, 14
  • [36] Association between cadmium exposure and serum neurofilament light chain levels: A nationwide population-based survey
    Luo, Jing
    Lin, Song
    ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY, 2024, 282
  • [37] Racial discrimination during middle age predicts higher serum phosphorylated tau and neurofilament light chain levels a decade later: A study of aging black Americans
    Simons, Ronald L.
    Ong, Mei Ling
    Lei, Man-Kit
    Beach, Steven R. H.
    Zhang, Yue
    Philibert, Robert
    Mielke, Michelle M.
    ALZHEIMERS & DEMENTIA, 2024, 20 (05) : 3485 - 3494
  • [38] Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis
    Mariotto, Sara
    Gajofatto, Alberto
    Zuliani, Luigi
    Zoccarato, Marco
    Gastaldi, Matteo
    Franciotta, Diego
    Cantalupo, Gaetano
    Piardi, Francesca
    Polo, Alberto
    Alberti, Daniela
    Sartori, Stefano
    Zanusso, Gianluigi
    Agro, Luigi
    Demurtas, Rita
    Sechi, GianPietro
    Sechi, Elia
    Monaco, Salvatore
    Ferrari, Sergio
    JOURNAL OF NEUROLOGY, 2019, 266 (07) : 1643 - 1648
  • [39] Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome
    Disanto, G.
    Adiutori, R.
    Dobson, R.
    Martinelli, V.
    Dalla Costa, G.
    Runia, T.
    Evdoshenko, E.
    Thouvenot, E.
    Trojano, M.
    Norgren, N.
    Lorscheider, J.
    Teunissen, C.
    Kappos, L.
    Giovannoni, G.
    Kuhle, J.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 176 - 177
  • [40] Serum Neurofilament light chain levels and disability milestones in Lewy body diseases
    Pilotto, A.
    Imarisio, A.
    Conforti, F.
    Lupini, A.
    Gianni, G.
    Gipponi, S.
    Cottini, E.
    Scalvini, A.
    Masciocchi, S.
    Nocivelli, S.
    Grasso, R.
    Turrone, R.
    Borroni, B.
    Rizzetti, M.
    Bonanni, L.
    Pizzi, M.
    Bellucci, A.
    Garraffa, E.
    Zetterberg, H.
    Ashton, N.
    Hye, A.
    Padovani, A.
    MOVEMENT DISORDERS, 2020, 35 : S156 - S157